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ABSTRACT Sympathetic neurons display considerable
plstict in the neurotrnmtter and neuropeptide phenotypes
they express in viro and in wivo. The cholinergic differentiation
factor (CDF, also known as leukemla inhibitory factor, LI)
induces cultured rat sympathetic neurons to become choliner-
gic, without affecting their survival or growth. To understand
the role of this factor in normal development, it is essential to
determine where it is produced in situ. To lo CDF/LIF
mRNA, a semiquantitative, reverse transcription-polymerase
chain reaction method was employed. Actinad tubulin mRNA
were used as internal controls, and two different sets of
CDF/LIF primers were compared. In patal rat peripheral
tissues, CDF/LIF mRNA was selectively localize in the target
area of developing, sympathetic cholinergic neurons; the
mRNA was not detected in the targets of sympathetic norad-
renergic neurons. This finding supports the hypothesis that
CDF/LIF is a target-derived neuronal differentiation factor.
In postnatal rat brain, CDF/LIF mRNA is azed selectively
in two parts of the visual system, visual cortex and superior
colliculus. Thus, CDF/LIF may play a role in this system as
well.
Neuronal phenotype can be influenced by environmental
factors (1-3), and culture assays have been used to identify
molecules that control phenotypic decisions. One such fac-
tor, cholinergic differentiation factor (CDF, also known as
leukemia inhibitory factor, LIF; ref. 4), is produced by
certain cultured non-neuronal cells and switches the pheno-
type of cultured rat sympathetic neurons from noradrenergic
to cholinergic (5). This protein is known to affect the prolif-
eration and differentiation of many cell types derived from
the earliest embryo to the adult (6). The pleiotropic effects of
this cytokine revealed in vitro raise the question of how and
where it acts in vivo. Moreover, since a number of distinct
proteins can induce cultured sympathetic neurons to become
cholinergic (7-10), it is essential to determine where and
when CDF/LIF and the other factors are produced in situ.
The sweat glands of the rat footpad are well-known targets
for cholinergic sympathetic neurons. During normal devel-
opment, noradrenergic sympathetic neurons are converted to
the cholinergic phenotype at the time their axons innervate
the glands (11). Moreover, footpads containing sweat glands
can induce noradrenergic sympathetic neurons that normally
innervate other targets in hairy skin to become cholinergic,
when the pads are transplanted to an ectopic site in the hairy
skin (12, 13). In addition, extracts of footpads contain an
activity that converts cultured sympathetic neurons from
noradrenergic to cholinergic (14). Therefore, sweat glands
represent a target tissue in which CDF/LIF could be local-
ized in vivo. Furthermore, since CDF/LIF can also enhance
the cholinergic properties of cultured central nervous system
neurons (15), it is also important to study the distribution of
this factor in the brain.
While it is possible to detect a CDF/LIF mRNA band in
total RNA from cultured heart cells (the source of CDF for
the original purification; ref. 16) by Northern hybridization
and RNase protection assays (unpublished results), it has
been difficult to detect a CDF/LIF signal in tissues such as
the rat footpad. Presumably this is due to the low abundance
of the CDF/LIF mRNA in vivo and the small amounts of
tissue available. These findings necessitated the use of the
more sensitive reverse transcription-polymerase chain reac-
tion (RT-PCR) method. Indeed, this method was recently
used to identify CDF/LIF transcripts in preimplantation
blastocysts (17).
MATERIALS AND METHODS
RNA Preparatio and PCR. Total RNA was extracted by
the acid/phenol method (18) from the tissues described. The
amount of total RNA was estimated by the DipStick system
(Invitrogen); 0.5 gg of total RNA was used for the cDNA
reactions. The volume of the cDNA reaction mixture, con-
taining random primer (pN6; ref. 19), was 20 pA. One to five
microliters of each cDNA reaction mixture was added to
make a final 25 or 50 1td of PCR mixture containing 100 ng of
either CDF/LIF primers, a-tubulin primers, or P-actin prim-
ers. Reaction mixtures were subjected to 40 cycles of PCR
(each consisting of 950C for 1 min, 57rC for 2 min, 720C for
3 min). Five microliters of each PCR mixture was applied to
an agarose (NuSieve GTG, FMC) gel, stained with ethidium
bromide, and visualized with UV light. The PCR products
subjected to analysis were therefore 1/200th (1/20 x 5/50) of
the total PCR products generated in each sample.
In an experiment to calibrate the method for detecting
CDF/LIF tralscripts, an authentic CDF/LIF transcript was
made by T7 RNA polymerase in vitro. Various amounts of
this transcript were added to 1 tg of total RNA extracted
from adult rat heart (Fig. 1).
Primers. The CDF/LIF primers used were 5'-CAATGC-
CCTCTITA1TTCCTATTACACAGC-3' and 5'-GGGGA-
CACAGGGCACATCCACATGGCCCAC-3'. The first, 5'
primer covered the junction between the second and third
exons (20). This choice was made to avoid a possible PCR
contamination from genomic template. The second, 3' primer
covered part of the third exon. The expected size of the PCR
product with these CDF/LIF primers is 333 base pairs (bp),
denoted by the arrowheads in the upper gels in Figs. 1 and 2.
An alternative 5' primer was also used (5'-CCGTGTCACG-
GCAACCTCATGAACCAGATC-3') that covered part ofthe
second exon; the expected size of the PCR product with this
primer and the 3' primer above is 396 bp. The tubulin primers
were 5'-CCTGGAACCCACAGTTATTGATGAAGT-
Abbreviations: CDF, cholinergic differentiation factor; LIF, leuke-
mia inhibitory factor; RT-PCR, reverse transcription-polymerase
chain reaction; Pn, postnatal day n.
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FIG. 1. CDF/LIF mRNA can be selectively detected in rat footpads. PCR used CDF/LIF primers (Upper) or control 8-actin or a-tubulin
primers (Lower) (see Materials and Methods). The experiments shown in A-D were independently conducted at different times. (A) Reaction
products from PCR amplification of serial dilutions ofa CDF/LIF transcript, plus 1 ,ug of total RNA extracted from adult rat heart. The following
amounts ofCDF/LIF template were used for lanes 1-10, respectively: 400 pg, 20 pg, 1 pg, 0.05 pg, 2.5 fg, 125 ag, 6.25 ag, 0.3 ag, 0.015 ag, none.
(B) RNA for PCR amplification was extracted from postnatal day 8 (P8) subcutaneous connective tissue (hairy skin area) (lane 2), P8 hairy skin
(lane 3), P8 footpad (lane 4), or P16 footpad (lane 5). Lane 1, no template; lane M, molecular size markers. (C) RNA for PCR amplification was
extracted from the lacrimal gland (lane 1), gut (lane 2), footpad (lane 3), skeletal muscle (lane 4), and submaxillary gland (lane 5) of P8 rats. (D)
RNA for PCR amplification was extracted from footpads of P4 (lane 1), P8 (lane 2), P16 (lane 3), P30 (lane 4), and 2-month-old (lane 5) rats.
cDNA for the actin assay was diluted 100-fold before use in the PCR amplification.
TCG-3' and 5'-AGAAGCCCTGGAGACCCGTGCACTG-
GTCAG-3' (21), and the size of the product is 200 bp. The
primers used in the actin assay were 5'-TCATGAAGTGT-
GACGTTGACATCCGTAAAG-3' and 5'-CCTAGAAG-
CATTTGCGGTGCACGATGGAGG-3' (22), and the size of
the product is 285 bp.
RESULTS
Specificity of the Assay. Conditions were established in
which the RT-PCR assay yielded increasing amounts of
product with addition of increasing amounts ofknown CDF/
LIFmRNA in the presence oftissueRNA that did not display
a CDF/LIF signal of its own (Fig. LA). A band of the correct
size (upper arrowhead) was detected within the range of
about 1-400 pg CDF/LIF mRNA (lanes 1-3), in the presence
A
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of total RNA from adult rat heart tissue, added before cDNA
synthesis. This dose-response curve was quite similar to that
obtained in the absence of added heart RNA (data not
shown). Thus the detection limit of the assay is between 0.05
and 1 pg per sample under these conditions. Additional
dilution experiments indicate that the limit is usually 0.2 pg.
These results also demonstrate that the absence of a positive
CDF/LIF mRNA signal in adult heart (lane 10) is not likely
to be due to an inhibitor ofthe PCR process; that is, the result
is not a false negative.
CDF/LIF Is Specifically Expressed in Footpads. A positive
CDF/LIF mRNA signal was obtained from the rat footpad,
a target of cholinergic sympathetic neurons. Total RNA from
P8 and P16 footpads (Fig. 1B, lanes 4 and 5) yielded a single
band of the size expected for CDF/LIF mRNA. While these
bands are weak in the reproduction, the signal was quite clear
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FIG. 2. CDF/LIF mRNA is not detected in a number of peripheral tissues. PCR used CDF/LIF (Upper) or actin (Lower) primers. Total
RNA (0.5 Ag) was extracted from various tissues and subjected to PCR amplification. (A) Lanes: 1, P7 heart; 2, P18 heart; 3, P9 hippocampus;
4, P19 hippocampus; 5, P18 liver; 6, P16 brain; 7, no template; 8, cultured heart cells [0.02 Aug of poly(A)+ RNA was used in this case instead
of 0.5 Ag of total RNA]. (B) Lanes: 1, P8 lacrimal gland; 2, P8 skin; 3, P8 gut; 4, P8 liver; 5, P8 skeletal muscle; 6, P8 submaxillary gland; 7,
P11 liver; 8, adult liver; 9, adult skeletal muscle; 10, adult liver (experiment independent from that in lane 8); 11, cultured heart cells; 12, no
template. (C) Lanes: 1, P8 parotid; 2, adult subcutaneous connective tissue; 3, adult heart; 4, adult liver; 5, adult hairy skin; 6, 1 pg ofCDF/LIF
RNA produced in vitro; 7, 400 pg of CDF/LIF RNA.
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in the original gel. Moreover, strong signals were seen in
other experiments, as shown below. The CDF/LIF signal
was selectively localized, since P8 hairy skin and subcuta-
neous connective tissue did not display this band; these
samples therefore contained <0.2 pg of CDF/LIF mRNA
(Fig. 1B, lanes 2 and 3). The significant a-tubulin signal
generated from the same RNA preparations (Fig. 1B, lanes 2
and 3, lower arrowhead) argues that the lack of a CDF/LIF
band was not due to a gross deficiency in total mRNA. The
lack of a CDF/LIF mRNA signal in the samples from
connective tissue and hairy skin is important because foot-
pads contain connective tissue and epidermis in addition to
sweat glands. Thus, these results suggest that the CDF/LIF
mRNA is indeed localized to the sweat glands.
CDF/LIF mRNA was also not detected in other P8 targets
of noradrenergic sympathetic neurons. Examples of such
tissues are lacrimal and submaxillary glands (Fig. 1C, lanes
1 and 5; Fig. 2B, lanes 1 and 6), liver (Fig. 2A, lane 5; Fig. 2B,
lanes 4, 7, 8, and 10; Fig. 2C, lane 4), parotid gland (Fig. 2C,
lane 1), and in vivo heart tissue (Fig:t A, lane 10; Fig. 2A,
lanes 1 and 2; Fig. 2C, lane 3). In addition, no CDF/LIF
signal was detected in P8 gut (Fig. 1C, lane 2; Fig. 2B, lane
3) or skeletal-muscle (Fig. 1C, lanes 2 and 4; Fig. 2., lanes
5 and 9). In most of these samples, strong actin bands
confirmed the-integrity of the RNA and the PCR procedures.
Positive controls in-these experiments included the clear
CDF/LIF signal in the footpad (Fig. 18, lane 4; Fig. 1C, lane
3; Fig. 1D))> and in cultured heart cells (the original source of
CDF isolation and purification; ref. 16) (Fig. 2A, lane 8; Fig.
2B, lane il)" As-well as-in vitro transcribed CDF/LIF mRNA
(Fig. LA, lanes 1-3; Fig, 2C, lanes 6 and 7). Therefore, these
results indicate that the-targets of noradrenergic sympathetic
neurons and-the targets of other cholinergic neurons (enteric
and spinal motor) do not contain detectable CDF/LIF
mRNA, at least at P8.
The sympathetic neurons that innervate the sweat glands
undergo the noradrenergic-to-cholinergic conversion after
their axons reach the footpads, beginning in the second
postnatal week (11). To determine whether CDF/LIF mRNA
is present in the footpads during this critical time, extracts
were made at several ages (Fig. iD). The relative intensity of
the CDF/LIF bands (upper gel) compared with those of
3-actin (lower gel) generated from the same samples indicates
that CDF/LIF mRNA levels are at their highest during the
time of initial innervation (P8, lane 2). The level prior to
innervation (P4, lane 1) appears to be less than at P8 and the
signal appears to decline following P8 (lanes 3-5). Given the
semiquantitative nature ofthe RT-PCR assay, these apparent
changes in CDF/LIF mRNA levels are necessarily tentative.
Nonetheless, similar results were obtained in three indepen-
dent experiments, including one using a different set of
primers for the CDF/LIF mRNA.
In the latter case, an alternative 3' primer that covers only
part of the second exon was used. When this primer plus the
5' primer previously employed were used, two bands were
observed from the PCR with footpad RNA. One band was of
the size expected for CDF/LIF (396 bp). The other band was
w1100 bp, the size expected for an exon-intron-exon se-
quence (data not shown). As described in Materials and
Methods, obtaining a band of the expected size with two
independent sets of CDF/LIF primers is important support
for the identity of the RT-PCR band from sweat-gland
extracts. The fact that the primer that spans the second and
third exons yielded only the lower band provides additional
evidence that the CDF/LIF band was not generated from
genomic templates.
CDF/LIF Expression In Brain. Since a CDF/LIF mRNA
band could be reliably detected in select peripheral tissues,
the same method was employed for a number of brain areas.
While a clear CDF/LIF mRNA band was found in extracts
from adult visual cortex and P17 superior colliculus (Fig. 3A),
no signal was detected in samples from various postnatal ages
of hippocampus (Fig. 2A, lanes 3 and 4), frontal cortex,
olfactory bulb, cerebellum, basal forebrain, and ventral
brainstem (Fig. 3B). The data in Fig. 3A andB come from the
same experiment, and actin mRNA was used as the internal
control to normalize the relative amounts of RNA in the
tissue samples. Since there were several bands present in
some of the samples from the CDF/LIF PCR, a second
CDF/LIF primer (5'-CAATGCCCTCTTTATITCCTATI7A-
CACAGC-3') was used in further experiments on these
various brain areas. No bands were detected in the size range
expected for CDF/LIF in the brain areas represented in Fig.
3B, whereas the CDF/LIF band was again observed in
extracts of adult visual cortex (data not shown).
DISCUSSION
A positive CDF/LIF signal was detected in footpadRNA and
not in a number of other tissues from postnatal rat. This
indicates that the RT-PCR method has not simply amplified
an extremely rare mRNA that is uniformly present in all
tissues, nor is it likely that the positive signal in footpads
represents contamination or a PCR artifact (23-26). The ratio
of the signal in sweat gland to that in the tissues where no
signal was detected is estimated to be at least 20:1 (5-10 pg
A
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FIG. 3. CDF/LIF mRNA is detected in particular brain areas, at specific stages. For the CDF/LIF assays (Upper), these primers were used:
5'-CAATGCCCTCITfTATTICCTATTACACAGC-3' and 5'-GGGGACACAGGGCACATCCACATGGCCCAC-3'. Actin primers were used
for control assays (Lower). (A)VC (visual cortex): 0, neonatal; 9, P9; 17, P17; A, adult. SC (superior colliculus): 0, neonatal; 17, P17. HC, cultured
heart cells. C, no template. M, size markers. (B) FC (frontal cortex), (LB (olfactory bulb), CBL (cerebellum), BG (basal forebrain), VBS (ventral
brainstem): 0, neonatal; 7, P7; 9, P9; 17, P17; A, adult. CONT (controls): HC, cultured heart cells; -, no template; M, size markers.
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in P8 footpads and a detection limit of 0.2 pg). It is of interest
that postnatal heart tissue RNA does not contain detectable
CDF/LIF mRNA, whereas cultured heart cell RNA does. It
is known that production ofCDF/LIF by heart cells is under
hormonal control (27). The result with heart tissue in vivo is
consistent with the fact that sympathetic neurons that inner-
vate the heart are noradrenergic. All of the other targets of
noradrenergic sympathetic neurons tested were also negative
for CDF/LIF mRNA (lacrimal, parotid and submaxillary
glands, liver, and hairy skin; the level ofRNA in the parotid
sample was low, however). Thus, there is a strong correlation
between the presence of CDF/LIF in peripheral tissues and
the phenotype of the sympathetic neurons innervating these
tissues (Table 1). In addition, the lack ofdetectable CDF/LIF
mRNA in heart and gut may indicate that this factor is not
responsible for the cholinergic phenotype of the parasympa-
thetic neurons that are found in these tissues. These conclu-
sions must remain tentative, however, until samples from
embryos are tested. The apparent developmental regulation
of the signal in footpads (Fig. 1D) illustrates the importance
of this qualification. Moreover, the cholinergic innervation of
the other muscles and glands tested occurs during embryonic
development, in contrast to the postnatal innervation of the
sweat gland.
The present results should also be integrated with those of
Rao and Landis (14). They have found that footpad homoge-
nates contain a factor(s) that induces cholinergic differenti-
ation in cultured sympathetic neurons. Most of this cholin-
ergic activity is not, however, precipitated with an antiserum
generated against the N-terminal region of CDF, nor is the
chromatographic behavior of the activity in the homogenate
identical to that of CDF purified from cultured heart cells.
These results suggest that the cholinergic factor in the
footpads may not be CDF/LIF (14), raising the possibility
that the CDF/LIF mRNA in this tissue is not translated into
protein. However, a negative posttranslational control of this
type would render the highly selective expression of the
CDF/LIF mRNA pointless. Alternatively, it is possible that
much of the cholinergic activity in the footpad homogenate is
due to another protein with cholinergic activity [likely to be
ciliary neurotrophic factor (CNTF); ref. 14; M. S. Rao, P. H.
Table 1. CDF/LIF mRNA expression
Tissue P0-4 P7-9 P16-19 Adult
Peripheral
Footpad (sweat gland) + + + + +
Connective tissue -
Skin
Parotid gland
Submaxillary gland -
Lacrimal gland
Heart - - -
Liver
Skeletal muscle
Gut -
Brain
Visual cortex - - + +
Superior colliculus - +
Olfactory bulb - - -
Cerebellum - - -
Basal forebrain - - -
Ventral brainstem - -
Frontal cortex
Hippocampus - -
+ +, Significant band (>1 pg of CDF/LIF mRNA per Mg of total
RNA) of the correct size; +, -1pg/Ig. + in the range 0.2-1 pg/Mg;
Patterson, and S. C. Landis, personal communication], one
that is released by homogenization but may not normally be
secreted by the sweat glands and would therefore not be a
true target-derived factor. Because of its lack of a conven-
tional signal sequence, CNTF may not be secreted; thus it has
been proposed that CNTF is a factor used in response to
nerve damage (28). According to this hypothesis, CDF/LIF
protein would also be present in the homogenate, but as a
minor cholinergic component. This possibility is supported
by the recent finding that antibodies that directly block the
activity of recombinant CDF/LIF are able to block the
activity of a minor fraction of the cholinergic activity in the
footpad extract (M. S. Rao, P. H. Patterson, and S. C.
Landis, personal communication).
Since CDF/LIF can influence the phenotype ofother types
of cultured neurons besides sympathetics (29, 30), it was of
interest to determine whether its mRNA could be detected in
the brain. Since the factor can alter the expression of many
neuropeptides and transmitters, and the particular genes
affected depend on the neurons being tested (30), it was
important to assay many brain areas, notjust those receiving
projections from the cholinergic basal forebrain (31). Sum-
marizing the results obtained thus far with brain, Table 1
shows that CDF/LIF mRNA levels are much higher in visual
cortex and superior colliculus than in other brain areas.
Therefore, the presence of the factor in postnatal brain does
not directly correlate with the presence of a cholinergic
projection from the basal forebrain. This does not preclude
that such a correlation may be found in embryonic brain,
however. The relatively late appearance of detectable CDF/
LIF mRNA in the visual system is unexplained at present.
Perhaps this factor is involved in an as yet undescribed
postnatal phenotypic plasticity. It is also possible that the
factor plays an entirely different role, unrelated to that
established in the peripheral nervous system. Phenotypic
plasticity has, however, been demonstrated for neurons from
various brain areas (e.g., refs. 32 and 33). While it is also
possible that the presence ofthe mRNA does not connote the
production of the CDF/LIF protein, the strong correlation of
the CDF/LIFmRNA with a particular neuronal phenotype in
the sympathetic system suggests that the presence of this
message in the visual system is indeed meaningful.
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